ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $54.01 and traded as low as $53.07. ProShares Ultra Nasdaq Biotechnology shares last traded at $54.71, with a volume of 3,854 shares trading hands.
ProShares Ultra Nasdaq Biotechnology Trading Up 0.6 %
The firm has a market cap of $59.25 million, a P/E ratio of 26.77 and a beta of 1.44. The stock has a 50 day simple moving average of $54.05 and a 200-day simple moving average of $57.89.
Institutional Trading of ProShares Ultra Nasdaq Biotechnology
Large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC increased its stake in ProShares Ultra Nasdaq Biotechnology by 31.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,326 shares of the exchange traded fund's stock worth $270,000 after acquiring an additional 1,266 shares during the last quarter. Jane Street Group LLC lifted its stake in ProShares Ultra Nasdaq Biotechnology by 8.4% in the third quarter. Jane Street Group LLC now owns 4,803 shares of the exchange traded fund's stock worth $306,000 after purchasing an additional 374 shares during the last quarter. Finally, Crowley Wealth Management Inc. bought a new stake in ProShares Ultra Nasdaq Biotechnology in the fourth quarter worth about $51,000.
About ProShares Ultra Nasdaq Biotechnology
(
Get Free Report)
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Further Reading
Before you consider ProShares Ultra Nasdaq Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares Ultra Nasdaq Biotechnology wasn't on the list.
While ProShares Ultra Nasdaq Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
